DWIGHT KING: Open Payments
NPI 1679574313 · WASHINGTON, DC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,573 in 193 payments from 18 companies in 2025. Trend: 2023 $2,716 · 2024 $2,825 · 2025 $3,573
Food & beverage: $3,573
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 13 | $449 |
| E.R. Squibb & Sons, L.L.C. | 15 | $358 |
| Neurocrine BioSciences, Inc. | 12 | $332 |
| Alkermes, Inc. | 15 | $303 |
| Otsuka America Pharmaceutical, Inc. | 15 | $288 |
| Supernus Pharmaceuticals, Inc. | 30 | $248 |
| Axsome Therapeutics, Inc. | 9 | $224 |
| Teva Pharmaceuticals USA, Inc. | 12 | $215 |
| Janssen Pharmaceuticals, Inc | 11 | $212 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $190 |
Products named: COBENFY, INGREZZA, REXULTI, Qelbree, ARISTADA, HETLIOZ, Auvelity, FANAPT.
Industry payments across DC — which companies pay providers there.
